Halozyme Therapeutics (HALO) Scheduled to Post Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is set to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Halozyme Therapeutics to post earnings of $0.64 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55 to $3.90 EPS and its FY 2024 guidance at 3.550-3.900 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. On average, analysts expect Halozyme Therapeutics to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Halozyme Therapeutics Trading Up 0.2 %

NASDAQ HALO opened at $39.91 on Friday. The firm has a market capitalization of $5.07 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.46 and a beta of 1.26. The business’s 50-day moving average price is $39.99 and its two-hundred day moving average price is $37.89. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 12 month low of $29.85 and a 12 month high of $45.00.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold 30,000 shares of company stock valued at $1,196,800 in the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 30th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Benchmark reaffirmed a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Finally, TD Cowen started coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.29.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.